1,4-Butanediol (BDO)-used as solvent and abused for its euphoric effects-is converted to gamma-hydroxybutyrate (GHB) by the enzyme alcohol dehydrogenase. This double-blind, placebo-controlled crossover study with six healthy volunteers is the first to date investigating the role of the ADH inhibitor fomepizole (4-methylpyrazole (4MP)) in moderating this conversion in humans. Participants received on two different days either intravenous placebo or 15 mg/kg 4MP followed by oral administration of 25 mg/kg BDO. Pretreatment with 4MP resulted in significantly higher BDO maximal plasma concentration (P = 0.001) and area under the concentration-time curve (AUC; P = 0.028), confirming that ADH is the primary pathway for the conversion of BDO to GHB in humans. With 4MP, the mean arterial pressure was significantly lower at 105 minutes compared to baseline (P = 0.003), indicating that blood pressure lowering, observed not with a temporal relationship to 4MP administration but after the maximum BDO concentration was reached, may be an intrinsic effect of BDO.
GHB concentrations within 5 minutes after oral administration. 14 Reported mean maximum drug concentration (C max ) after administration of 25 mg/kg BDO is 3.8 mg/L, with time of maximum concentration (T max ) of 26 minutes and elimination half-life (t 1/2 ) of 39 minutes. 14 The metabolism of BDO is thought to be the same as that of ethanol, with a two-step conversion of BDO to GHB via the hepatic enzyme alcohol dehydrogenase (ADH) to gamma-hydroxybutyraldehyde and then by aldehyde dehydrogenase to GHB 15, 16 ( Figure 1 ). When ethanol is coingested with BDO, as is frequently the case in the setting of recreational drug use, this pathway may be competitively blocked, 17, 18 whereas BDO itself has been shown to potentiate the effects of ethanol in rats. 16 Ethanol competitively inhibited the conversion of BDO to GHB with an apparent K i of 6.5 × 10 −3 M in the rat brain and 2.7 × 10 −3 M in the rat liver. 16 Fomepizole (also known as 4-methylpyrazole (4MP)) is a potent competitive inhibitor of ADH 19 that is used to treat both methanol and ethylene glycol poisoning. 20 Pretreatment with 4MP in mice increased the toxic dose-50 of BDO 10-fold for the righting reflex and 30-fold for the rotarod test, two established assessments demonstrating neurologic deficits produced by pharmacological treatments, 21 indicating decreased toxicity presumably due to inhibition of the conversion of BDO to GHB.
To date, no study has examined the role of 4MP in moderating the conversion of BDO to GHB in humans. The aim of the present study was to characterize the pharmacokinetics of orally administered BDO after pharmacological inhibition of ADH by 4MP. We hypothesized that 4MP would block the conversion of BDO to GHB, resulting in persistently high BDO concentrations and low GHB concentrations after pretreatment with 4MP. This would support the hypothesis that ADH is responsible for the conversion of BDO to GHB. Secondary outcomes included assessing the clinical effects of BDO, as the observations in the presence of persistently high BDO concentrations could help gain a better understanding of the effects of BDO, separately from the effects of its metabolite, GHB.
RESULTS
The mean age of participants was 25.5 years (SD 4.8), and selfreported races were four white, one Black, and one Asian. The mean body mass index was 24.1 kg/m 2 (SD 2.4). By self-report, three volunteers (50%) were cigarette smokers. Mean selfreported alcohol intake was 65 g/week (SD 54.9). The mean administered doses of 4MP and BDO were 1,017 mg (SD 155, range 842-1,235) and 1,695 mg (SD 258, range 1,403-2,058), respectively. Bold numbers indicate significant differences (P < 0.05) between the two arms. 4MP, fomepizole; AUC, area under the plasma concentration-time curve; inf, extrapolation to infinity; last, until last measured concentration; CL/F, oral clearance; C max , maximum concentration; N/A, not applicable; t 1/2 , elimination half-life; T max , time of maximum concentration. a n = 3 (for the other three all concentrations below limit of quantification/not detected).
Pharmacokinetics
The pharmacokinetics of BDO and GHB for both conditions are summarized in Tables 1 and 2 , respectively. BDO was rapidly metabolized to GHB in the placebo arm, with three participants having no detectable BDO at any time postdosing (Table 1, Figure 2 ).
In the 4MP arm, BDO was measurable in all participants up to 360 minutes (after this timepoint, not detectable/below limit of quantification (LOQ) in four and very close to LOQ in two cases), whereas GHB was not detectable above 5 μg/mL in either arm after 180 minutes (Figures 2 and 3) . The last quantifiable GHB concentration (2.5 μg/mL) was measured at 180 minutes in the placebo arm and at 240 minutes in the 4MP arm. After these timepoints, all values were not detectable/below LOQ.
In the 4MP arm, a BDO mean C max of 29.8 μg/mL was reached with a median T max of 30 minutes, compared to a mean C max of 3.6 μg/mL (P = 0.001) and T max of 15 minutes (P = 0.18) in the placebo arm ( Table 1) . A significant difference between the two arms was also seen regarding the area under the BDO plasma concentration-time curve until last measurable concentration (AUC last ; P = 0.028). The mean t 1/2 of BDO was 162.3 minutes with 4MP pretreatment, although its calculation was not possible in the placebo arm due to values below (n = 3) or fluctuating values very close to LOQ (n = 3), thus not allowing a confident estimation (Table 1, Figure 2) . Consequently, calculation of the extrapolated AUC to infinity (AUC inf ) for which the t 1/2 is needed and the oral clearance which is based on the AUC inf was also not possible for these cases.
Conversely, GHB levels were low in the 4MP arm and high in the placebo arm, with mean C max of 10.9 μg/mL and 50.4 μg/ mL, respectively (P = 0.001; Table 2 ). The t 1/2 of GHB was significantly longer after 4MP (85 minutes) compared to after placebo (35 minutes) (P = 0.008). Further significant differences between the two arms were seen regarding the GHB AUC last (P = 0.028) and the AUC inf (P = 0.003; Table 2 ).
Clinical effects
The mean heart rate (HR) and mean arterial pressure (MAP) over time during 4 hours after BDO administration are shown in Figure 4 .
There were no significant differences regarding the HR and the oxygen saturation between the two arms or compared to the baseline. Higher MAP values were seen in the placebo arm compared to the 4MP arm at various timepoints ( Figure 4) ; however, after adjusting for multiple comparisons using the Bonferroni correction, those differences were not significant. Compared to the baseline and after performing the Bonferroni correction for multiple comparisons, significantly lower MAP Table 2 Pharmacokinetics of gamma-hydroxybutyrate after pretreatment with placebo and 4MP (mean (SD) or median (range)) (n = 6, unless indicated otherwise) 
0.003
Bold numbers indicate significant differences (P < 0.05) between the two arms. 4MP, fomepizole; AUC, area under the plasma concentration-time curve; inf, extrapolation to infinity; last, until last measured concentration); CL/F, oral clearance; C max , maximum concentration; T 1/2 , elimination half-life; T max , time of maximum concentration. a n = 5 (T 1/2 , and consecutive AUC inf , due to very low concentrations not calculable in one case). values were seen in the 4MP arm at 105 minutes (P = 0.003), whereas no significant differences to baseline were seen in the placebo arm. There were no significant differences in subjective responses between the 4MP and placebo arm or compared to baseline after adjusting for multiple comparisons using the Bonferroni correction. The graphs of the mean scores for all visual analog scale (VAS) questionnaires over time in both treatment arms can be found in Figure S1 . Figure 5 shows the mean VAS score differences to baseline at 30, 60, and 90 minutes after BDO administration in both treatment arms. There were no significant differences regarding the mean VAS score differences to baseline between the 4MP and placebo arm.
DISCUSSION
We present novel data in humans showing that pretreatment with 4MP prior to BDO resulted in significantly higher BDO Figure 3 Mean (± SE) plasma concentrations of gamma-hydroxybutyrate (GHB) over time in both conditions (inset: semilogarithmic plot of the data; 4-methylpyrazole (4MP): fomepizole; n = 6, except at 5 and 720 minutes in the placebo arm and at 45 minutes in the 4MP arm (n = 5 due to missing data)). Figure 4 Mean (± SE) (a) heart rate and (b) mean arterial pressure (MAP) over time in the fomepizole (4-methylpyrazole (4MP)) (n = 6, except at 30 and 45 minutes for MAP (n = 5)) and the placebo arm (n = 6, except at 105 minutes (n = 5)). Timepoints marked with x indicate significant difference (P = 0.003) compared to baseline after adjusting for multiple comparisons using the Bonferroni correction. and lower GHB plasma concentrations and AUC, supporting the idea that ADH is the major pathway for the conversion of BDO to GHB. We did observe some production of GHB after BDO in the presence of 4MP. It is unknown if 4MP incompletely blocks the metabolism of BDO to GHB via ADH or if there are alternative pathways for this conversion. Furthermore, 4MP pretreatment significantly increased the t 1/2 of GHB compared to placebo, which might indicate inhibition of the GHB dehydrogenase (one of the enzymes primarily involved in GHB metabolism 22, 23 ) by 4MP. Subjective effects of BDO were not significantly affected by 4MP treatment, but blood pressure was significantly lower after 4MP compared to placebo. The latter observation could indicate an intrinsic effect of BDO or an effect of 4MP itself.
Reported recreational BDO doses are in the range of 1-14 g in nonfatal and 5.4-20 g (88-300 mg/kg) in fatal cases.
11 Reported blood BDO concentrations are 82 μg/mL in one nonfatal intoxication (dose not reported) 12 and 220 μg/mL in another fatal case after ingestion of 5.4-10.8 g (95-189 mg/kg). 11 The BDO dose and blood concentrations in these cases far exceed those observed in our study.
In a previous study on the pharmacokinetics of BDO using the same oral dose as in the present study, 14 BDO levels were similar to the present study, showing rapid and extensive conversion to GHB. Also similar to the placebo arm in the present study, participants in the study of Thai et al. reported feeling less alert, decreased concentration, and more lightheaded. These findings are in line with known GHB effects from previous studies in which similar GHB concentrations were reached 24, 25 and when 25 mg/kg GHB was administered, 26 thus supporting the idea that in normal conditions (i.e., no coadministration of other substances) the main effects of BDO are mediated through the action of its metabolite GHB. 8 4MP is a potent competitive inhibitor of ADH and is used clinically in the management of ethylene glycol 27 and methanol poisoning. 28 It is dosed intravenously over 30 minutes every 12 hours, with adjustments for hemodialysis. 29 Potential side effects of 4MP include burning at the infusion site, headache, nausea, dizziness, agitation, eosinophilia, and seizures, although it is unknown whether some of those effects are due to 4MP treatment or the patient's poisoning. 20, [27] [28] [29] [30] [31] Inhibition of the BDO metabolism by 4MP has been shown in vitro 15, 32 and in animal models. 15, 21, 33 As far as we know, the possible utility of 4MP in prevention of GHB toxicity from BDO in humans has been investigated in only one case report. 34 The patient presented with seizures and coma following ingestion of ~3 g BDO; 10 mg/kg 4MP were administered every 12 hours (total of three doses). The BDO plasma concentrations at presentation and at 3 and 8 hours after presentation were 24 μg/mL, 20 μg/mL, and undetectable, respectively (delay between ingestion and presentation unknown). The corresponding GHB plasma concentrations were 222 μg/mL, 310 μg/mL, and undetectable, respectively. The patient regained normal consciousness 3 hours after 4MP administration. Considering the very rapid conversion of BDO to GHB, it is unknown whether 4MP has actually influenced the recovery course in this case. 26 However, 4MP treatment might provide a potential clinical benefit as antidote in cases of BDO intoxication for patients with slower conversion of BDO to GHB (e.g., in cases of ethanol coingestion or due to ADHvariant haplotypes associated with slower metabolism). 14 Because of its rapid metabolism to GHB, the physiological actions of BDO itself are currently unknown. Potential alcohol-like effects have been postulated in a previous study 17 based on the potentiation of some effects when BDO was coadministered with ethanol, but this might have resulted by the potentiation of ethanol's effects due to competition for the same metabolic enzymes. 16 In our study, the significant difference regarding lower blood pressure in the 4MP arm could represent intrinsic effects of BDO. However, we cannot exclude the possibility that the pretreatment with 4MP and not BDO itself caused the observed effects. Although hypotension is not reported among the common adverse effects of 4MP, 20 it has (rarely) occurred according to the product label 29 and there is also one case report available documenting severe hypotension and bradycardia immediately after intravenous fomepizole infusion. 35 The significant lower MAP values in our study were not documented with a close temporal relationship to 4MP administration but after BDO reached its C max in the majority of the participants, suggesting that BDO and not 4MP was responsible for these changes.
Limitations of our study include the small sample size, which reduced power to detect differences in subjective responses and did not allow subgroup analysis as sex and racial comparisons. Moreover, a relatively small BDO dose was administered, thus not allowing for a generalization of our findings in cases of BDO recreational use where, usually, higher doses are consumed. Furthermore, no genetic analysis of ADH gene variants with reduced activity was performed. Finally, 4MP was administered before BDO, which would not be the case in a real-life clinical scenario with 4MP use as an antidote. Despite these limitations, our study unequivocally demonstrates that 4MP markedly inhibits the conversion of BDO to GHB in humans.
In summary, pretreatment with intravenous 15 mg/kg 4MP in healthy individuals significantly inhibited the metabolism of BDO to GHB, resulting in significantly higher C max and AUC of BDO and lower C max and AUC of GHB. These findings indicate that ADH is a major pathway for the conversion of BDO to GHB in humans; further investigation of the utility of 4MP as an antidote in cases of BDO intoxication to prevent GHB toxicity is warranted.
METHODS
Six consented, healthy volunteers (three men, three women) between the ages of 18 and 45 years participated in a double-blinded, randomized, placebo-controlled, two-arm, crossover study, in which participants received either intravenous placebo (one arm) or 15 mg/kg 4MP (other arm; recommended loading dose for ethylene glycol/methanol poisoning 20 ) followed by oral administration of 25 mg/kg BDO (a relatively low dose considering reported recreational doses 11 ). The washout period between treatments was a minimum of 2 days.
To avoid first-time exposure to a potentially addictive drug, individuals who were drug-naive (defined as not having ingested GHB, BDO, or related analogues on at least one occasion in the past) were excluded. Also excluded were individuals with a history of illicit drug abuse (other than GHB or cannabis) as assessed by questionnaires or positive urine toxicology test, including the following drugs of abuse: amphetamine/ methamphetamine/3,4-methylenedioxy-methamphetamine, barbiturates, benzodiazepines, cocaine, opiates, methadone, and ethanol. Exclusion criteria also included significant medical history (e.g., cardiac disease, hypertension, and psychiatric condition), conditions requiring regular medication use (with the exception of oral contraceptives), obesity (i.e., body mass index ≥ 30), pregnancy or breastfeeding, alcohol abuse, and history of discomfort or difficulties with blood draws. Written informed consent was obtained before enrollment and the study was approved by the Committee on Human Research at the University of California, San Francisco.
Eligibility was determined at a screening visit, including questionnaires, a simple physical examination (vital signs, weight, and height), electrocardiogram, baseline blood chemistries, and urine testing (for toxicology and pregnancy, if applicable). Eligible participants were then scheduled for two separate inpatient study treatment visits. Participants were asked to abstain from certain substances prior to the study day: alcohol and recreational drugs (3 days), over-the-counter medications (3 days) and dietary supplements (1 week), caffeinated beverages and any food (both from midnight the prior evening), and any prescription medications that could be safely stopped (1 week).
Participants were admitted to the General Clinic Research Center of the Zuckerberg San Francisco General Hospital the morning of the study day at 7 am, and a single intravenous catheter was placed upon arrival. Doses of 4MP (Antizol, Paladin Labs, St-Laurent, Quebec, Canada)/ placebo were prepared by the hospital pharmacy, representing a total dose based on 15 mg/kg and diluted in 100 mL normal saline (or just saline for placebo). The drug was administered intravenously at 8 am over 30 minutes and was completed 30 minutes prior to BDO dosing (choice of latency time based on the reported T max of 30 minutes to 2 hours following an oral 4MP dose 36 ). Doses of BDO were prepared by the hospital pharmacy, representing a total dose based on 25 mg/kg in liquid form and administered orally in water or juice 30 minutes after the end of the 4MP/placebo infusion.
Blood specimens were collected at 0, 5, 15, 30, 45, 60, and 90 minutes and 2, 3, 4, 5, 6, 12, 24, and 36 hours after BDO dosing. Plasma samples were frozen and stored for analysis of BDO and GHB concentrations. Plasma was analyzed by gas chromatography-mass spectrometry for BDO and GHB (LOQ 2 and 2.5 μg/mL, respectively), as described previously 14 ; the original method was slightly modified (sonication during derivatization) to improve reproducibility, also resulting in different LOQs. Vital signs were continuously monitored. The MAP was calculated from the systolic and diastolic blood pressure (SP and DP, respectively) using the formula: MAP = DP + 1/3 (SP − DP). Subjective drug effects (i.e., light headed, nausea, shaky/jittery, palpitations, sweaty, flushed, headache, alert, concentration, calm/relaxed, happy/upbeat, and irritable/tense) were assessed by VAS questionnaires at 0, 30, 60, and 90 minutes and 2, 4, and 6 hours. Participants were discharged in the evening after the closeout of the 36 hours.
Plasma concentration-vs.-time data for BDO and GHB were evaluated by noncompartmental analysis using WinNonlin (version 6.3; Pharsight Corporation, Mountain View, CA). The t 1/2 was calculated from the slope of the linear portion of the log plasma concentration-vs.-time curve. The T max and C max were obtained from the individual plasma concentration data. The AUC was calculated using the trapezoidal rule and was extrapolated from the AUC last to AUC inf . The oral clearance was estimated by dividing the oral dose by the AUC inf .
Numerical data are presented as mean and SD if normally distributed and as median and range if not normally distributed. Baseline of vital signs (HR, MAP, and oxygen saturation) was defined as the average of measurements taken at time 60 and 75 minutes before BDO dosing (i.e., before 4MP administration), baseline of VAS scores as the first VAS questionnaire assessment at time 0 (time of BDO administration). For analysis of differences in the VAS scores compared to baseline, the difference for each timepoint equals the VAS score at this timepoint minus the VAS baseline score. For graphic representation and descriptive results, concentrations documented as below LOQ/ not detected were replaced by 0 and were left blank if no sample was available. Hemodynamic variables were tested by pair-wise comparisons using the paired t test. Pharmacokinetic data and VAS scores were tested using the paired t test for normally distributed variables and the Wilcoxon Signed Rank Test for nonparametric results. Due to the 11 and 6 pairwise comparisons in the hemodynamic variables and the VAS scores, respectively, Bonferroni correction was applied. A P value < 0.05 was considered statistically significant. Data analysis was performed using SPSS statistical software (IBM (Armonk, NY) SPSS Statistics 23.0). 
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